pdf   xlsx method abbreviations

metastatic/advanced - colorectal cancer (mCRC), Immune checkpoint association , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.72 [0.54, 0.96]< 10%1 study (1/-)98.6 %NAnot evaluable crucial-
progression or deaths (PFS) 1.01 [0.76, 1.34]< 10%1 study (1/-)47.3 %NAnot evaluable important-
DCR 4.16 [1.40, 12.33]> 10%1 study (1/-)99.5 %NAnot evaluable non important-
objective responses (ORR) 1.03 [0.03, 31.00]> 10%1 study (1/-)50.6 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 40.67 [2.31, 714.82]< 10%1 study (1/-)0.6 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.